Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Distribution of Endoscopic and Histologic Healing in Ulcerative Colitis
NL-OMON55788Active, not recruiting
- Sponsor
- Alimentiv Inc.
- Start
- Jan 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in autoimmune colitis (5 cohorts), sponsored by Alimentiv Inc. Primary endpoints: Anatomic distribution of endoscopic improvement and Anatomic distribution of histologic improvement. Started Jan 2020; status: active, not recruiting.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON55788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55788.